OA
RPTX

Oracle Alpha’s Repare Therapeutics RPTX Stock Holding History

Oracle Alpha’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$91.8K Buy
19,482
+7,194
+59% +$46.1K 0.16% 178
2023
Q4 		$89.7K Buy
+12,288
New +$68.8K 0.12% 240

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Oracle Alpha's RPTX Position: Q1 2024 in Review

Oracle Alpha increased its Repare Therapeutics (RPTX) stake by 59% in Q1 2024, buying an estimated $46.1K and bringing the position to 19,482 shares worth $91.8K. The position accounts for 0.16% of the portfolio, ranked #178.

Oracle Alpha first reported a position in RPTX in Q4 2023 and has held it in 2 quarters since. 71 funds tracked by Wall St. Rank hold RPTX as of Q1 2024.

  • Oracle Alpha held 19,482 shares of Repare Therapeutics worth $91.8K as of Q1 2024.
  • Oracle Alpha bought 7,194 Repare Therapeutics shares in Q1 2024, an estimated $46.1K.
  • Repare Therapeutics made up 0.16% of Oracle Alpha's portfolio in Q1 2024, its #178 holding.
  • Oracle Alpha first reported a position in Repare Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 71 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.